Chemomab Therapeutics (CMMB) announced that its lead product nebokitug has been awarded new patent protections in China and Russia. Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, commented, “These newly granted patents further strengthen the company’s extensive intellectual property portfolio for nebokitug, reinforcing its leading strategic position in primary sclerosing cholangitis (PSC) established by the positive data from the nebokitug Phase 2 SPRING trial, which we believe represents the most promising clinical results to date in this debilitating and potentially lethal disease that lacks effective treatment. Furthermore, for the first time the FDA has aligned on a clear and straightforward pathway to regulatory approval in PSC. We have amassed a large and comprehensive intellectual property portfolio for nebokitug and are pleased to add these new patents in China and Russia, two significant territories for future commercialization. Enlarging the scope of our patent protections is especially relevant as we continue to advance potential partnerships to support a nebokitug Phase 3 registrational trial in PSC.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMMB:
- Chemomab Therapeutics Announces Annual General Meeting for July 2025
- Chemomab Therapeutics: Promising Prospects with Streamlined Path to Approval and Strategic Advancements
- Chemomab Therapeutics Advances Nebokitug for PSC Treatment
- Chemomab Therapeutics price target lowered to $10 from $11 at Oppenheimer
- Chemomab Therapeutics Advances Nebokitug Towards Phase 3 After Positive Trial Results